Assenagon Asset Management S.A. Acquires 134,043 Shares of Aveanna Healthcare Holdings Inc. $AVAH

Assenagon Asset Management S.A. lifted its holdings in shares of Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) by 16.4% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 951,594 shares of the company’s stock after purchasing an additional 134,043 shares during the period. Assenagon Asset Management S.A.’s holdings in Aveanna Healthcare were worth $6,128,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of AVAH. Caitong International Asset Management Co. Ltd increased its holdings in Aveanna Healthcare by 252.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,351 shares of the company’s stock valued at $27,000 after purchasing an additional 2,400 shares during the period. Quantbot Technologies LP acquired a new position in Aveanna Healthcare during the 2nd quarter worth about $43,000. EverSource Wealth Advisors LLC lifted its holdings in Aveanna Healthcare by 88,100.0% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 11,466 shares of the company’s stock worth $102,000 after buying an additional 11,453 shares during the period. Entropy Technologies LP bought a new stake in shares of Aveanna Healthcare in the 3rd quarter valued at about $107,000. Finally, Oxford Asset Management LLP bought a new stake in shares of Aveanna Healthcare in the 2nd quarter valued at about $64,000. Institutional investors own 87.96% of the company’s stock.

Insider Transactions at Aveanna Healthcare

In other Aveanna Healthcare news, insider Patrick A. Cunningham sold 125,000 shares of the stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $7.59, for a total value of $948,750.00. Following the transaction, the insider owned 212,755 shares in the company, valued at approximately $1,614,810.45. This represents a 37.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Paul R. Vigano sold 1,000,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $8.00, for a total value of $8,000,000.00. Following the completion of the sale, the insider directly owned 245,251 shares of the company’s stock, valued at $1,962,008. This trade represents a 80.31% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 22,886,629 shares of company stock valued at $148,119,440. 5.30% of the stock is currently owned by corporate insiders.

Aveanna Healthcare Price Performance

Shares of AVAH opened at $8.64 on Monday. Aveanna Healthcare Holdings Inc. has a 52-week low of $3.73 and a 52-week high of $10.32. The company has a debt-to-equity ratio of 5.35, a quick ratio of 1.47 and a current ratio of 1.47. The business’s 50 day moving average price is $7.14 and its two-hundred day moving average price is $7.57. The firm has a market cap of $1.88 billion, a PE ratio of 7.32, a price-to-earnings-growth ratio of 0.89 and a beta of 1.93.

Aveanna Healthcare (NASDAQ:AVAH) last announced its quarterly earnings data on Thursday, May 14th. The company reported $0.18 EPS for the quarter, topping the consensus estimate of $0.13 by $0.05. The company had revenue of $647.91 million during the quarter, compared to the consensus estimate of $613.22 million. Aveanna Healthcare had a net margin of 10.37% and a return on equity of 124.68%. The company’s revenue for the quarter was up 15.9% on a year-over-year basis. On average, equities analysts anticipate that Aveanna Healthcare Holdings Inc. will post 0.65 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on AVAH shares. Barclays lowered their price objective on Aveanna Healthcare from $9.50 to $9.00 and set an “overweight” rating for the company in a research report on Monday, May 18th. Royal Bank Of Canada upgraded Aveanna Healthcare from a “sector perform” rating to an “outperform” rating and set a $10.00 target price on the stock in a report on Wednesday, June 3rd. Raymond James Financial raised shares of Aveanna Healthcare from an “outperform” rating to a “strong-buy” rating and set a $13.00 target price for the company in a research report on Friday, March 20th. Stephens upgraded shares of Aveanna Healthcare from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $10.00 to $11.00 in a research report on Friday, May 15th. Finally, BMO Capital Markets reduced their price objective on shares of Aveanna Healthcare from $11.00 to $10.00 and set an “outperform” rating on the stock in a research note on Friday, March 20th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and five have given a Hold rating to the company. According to MarketBeat, Aveanna Healthcare has an average rating of “Moderate Buy” and an average target price of $10.50.

Aveanna Healthcare Company Profile

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.